Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

被引：0
|
作者：
Rita Nahta
Dihua Yu
Mien-Chie Hung
Gabriel N Hortobagyi
Francisco J Esteva
机构：
[1] Instructor at the Department of Breast Medical Oncology,Departments of Breast Medical Oncology and Molecular & Cellular Oncology
[2] Professor at the Departments of Surgical Oncology and Molecular and Cellular Oncology,undefined
[3] Professor in the Department of Molecular and Cellular Oncology,undefined
[4] Chairman and Professor in the Department of Breast Medical Oncology,undefined
[5] Director of the Breast Cancer Translational Research Laboratory and Associate Professor,undefined
[6] University of Texas MD Anderson Cancer Center,undefined
来源：
Nature Clinical Practice Oncology | 2006年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Despite the impressive results seen in phase II trials of trastuzumab, many tumors that overexpress HER2 show resistance to the drug. Understanding the molecular mechanisms underlying primary or treatment-induced trastuzumab resistance is critical to improving the survival of patients with metastatic breast cancer with aggressive HER2 overexpressing tumors. This review discusses the novel therapeutic strategies that target the aberrant molecular pathways, and explains how these strategies could greatly improve the duration of response to trastuzumab.
引用
收藏
页码：269 / 280
页数：11
相关论文
共 50 条
  • [41] Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
    Zongbi Yi
    Guohua Rong
    Yanfang Guan
    Jin Li
    Lianpeng Chang
    Hui Li
    Binliang Liu
    Wenna Wang
    Xiuwen Guan
    Quchang Ouyang
    Lixi Li
    Jingtong Zhai
    Chunxiao Li
    Lifeng Li
    Xuefeng Xia
    Ling Yang
    Haili Qian
    Xin Yi
    Binghe Xu
    Fei Ma
    npj Breast Cancer, 6
  • [42] Predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer
    Morganti, Stefania
    Li, Tianyu
    Santos, Katheryn
    Hughes, Melissa
    Priedigkeit, Nolan
    Li, Yvonne
    Lipsyc-Sharf, Marla
    Kirkner, Gregory
    Files, Janet
    Kasparian, Julie
    Grant, Elizabeth
    Gupta, Gunjan
    Curigliano, Giuseppe
    Tolaney, Sara
    Cherniack, Andrew
    Tayob, Nabihah
    Lin, Nancy
    Parsons, Heather
    CANCER RESEARCH, 2024, 84 (09)
  • [43] The role of PP2A in innate resistance to HER2-targeted therapy
    Conlon, N.
    McDermott, M.
    Crown, J.
    O'Donovan, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Interleukin-6 expression is involved in the response to HER2-targeted therapy in breast cancer
    Chen, Y. -J.
    Chien, P. -H.
    Pan, H. -L.
    Huang, W. -C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [45] Carnitine palmitoyltransferase IA: an emerging potential metabolic target to counteract HER2-targeted therapy resistance in HER2-positive breast cancer
    Franceschini, Alma
    Castagnoli, Lorenzo T.
    Triulzi, Tiziana Iindt
    Corsetto, Paola Antonia
    Dugo, Matteo
    Belfiore, Antonino
    Vingiani, Andrea
    Signati, Lorena
    Mazzucchelli, Serena
    Corsi, Fabio
    Ligorio, Francesca
    Tagliabue, Elda
    Vernieri, Claudio
    Pupa, Serenella M.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [46] HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer
    Pereira, Patricia M. R.
    Ragupathi, Ashwin
    Shmuel, Shayla
    Mandleywala, Komal
    Viola, Nerissa T.
    Lewis, Jason S.
    MOLECULAR PHARMACEUTICS, 2020, 17 (01) : 327 - 337
  • [47] Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
    Yi, Zongbi
    Rong, Guohua
    Guan, Yanfang
    Li, Jin
    Chang, Lianpeng
    Li, Hui
    Liu, Binliang
    Wang, Wenna
    Guan, Xiuwen
    Ouyang, Quchang
    Li, Lixi
    Zhai, Jingtong
    Li, Chunxiao
    Li, Lifeng
    Xia, Xuefeng
    Yang, Ling
    Qian, Haili
    Yi, Xin
    Xu, Binghe
    Ma, Fei
    NPJ BREAST CANCER, 2020, 6 (01)
  • [48] A decade of HER2-targeted therapy in older patients with invasive breast cancer at Institut Curie
    Geiss, R.
    Pierga, J-Y.
    Auclin, E.
    De Lempdes, G.
    Trad, F. Rollot
    Cottu, P.
    Giard, C.
    Stevens, D.
    Brain, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
    Nielsen, Dorte Lisbet
    Andersson, Michael
    Kamby, Claus
    CANCER TREATMENT REVIEWS, 2009, 35 (02) : 121 - 136
  • [50] Implications of HER2-Targeted Therapy on Extent of Surgery for Early-Stage Breast Cancer
    Aziz, Hamza
    Marcom, P. Kelly
    Hwang, E. Shelley
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (05) : 1404 - 1405
12345